Metrohm helps pharma to bring their USP methods up to date

John­son & John­son, As­traZeneca and Pfiz­er lead­ers re­it­er­at­ed dur­ing the JP Mor­gan Health­care Con­fer­ence that the fed­er­al gov­ern­ment’s price ne­go­ti­a­tions still won’t have a ma­te­r­i­al

One of Catal­ent’s three sites at the cen­ter of the No­vo-Catal­ent deal has been hit by at least three form 483s in the past two